The FDA has expanded use of elexacaftor/tezacaftor/ivacaftor for children aged 2 to 5 years with cystic fibrosis with certain mutations, according to a press release from Vertex Pharmaceuticals.This new approval applies to children in this age range who possess at least one F508del mutation in the CFTR gene or a mutation in the CFTR gene that responds to elexacaftor/tezacaftor/ivacaftor
Vertex Pharma (VRTX) Announces FDA Approval of TRIKAFTA streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
-About 900 children with cystic fibrosis will now have a medicine to treat the underlying cause of their disease for the first time- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced